2016 American Society of Clinical Oncology Annual Meeting *

June 3-7, 2016; Chicago, Illinois
This program provides coverage of the 2016 ASCO annual meeting with PowerPoint summaries and expert analysis of the most clinically relevant study results with downloadable highlights slidesets. Topics include multiple solid tumors and hematologic malignancies.

Share

Program Content

Activities

GU Malignancies Chicago 2016
GU Malignancies at the 2016 Clinical Oncology Meeting: In Anticipation of Practice-Changing Data
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: May 31, 2016

Expires: May 30, 2017

Atezolizumab in Pretreated mUC
IMvigor 210 (Cohort 2): Atezolizumab in Pretreated Metastatic Urothelial Carcinoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2016

Expires: June 05, 2017

Atezolizumab in First-line mUC
IMvigor 210 (Cohort 1): First-line Atezolizumab in Cisplatin-Ineligible Metastatic Urothelial Carcinoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2016

Expires: June 05, 2017

QoL With Docetaxel + ADT in mHSPC
CHAARTED: QoL Analysis of Docetaxel + ADT in Metastatic Hormone-Sensitive Prostate Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2016

Expires: June 06, 2017

Cabazitaxel vs Docetaxel in mCRPC
FIRSTANA: Cabazitaxel Not Superior to Docetaxel in Chemotherapy-Naive mCRPC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2016

Expires: June 06, 2017

Radium-223 Retreatment
Retreatment With Radium-223 Safe, Showing Activity in Patients With CRPC and Bone Metastases
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2016

Expires: June 06, 2017

Nivo Beyond Progression in RCC
Potential Benefit of Nivolumab Treatment Beyond Progression in Advanced RCC: Subgroup Analysis of CheckMate 025
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2016

Expires: June 08, 2017

Atezolizumab Predictors of Response
IMvigor210: Predictors of Response to Atezolizumab in mUC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 14, 2016

Expires: June 13, 2017

Downloadable Slideset
Genitourinary Cancers
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: August 12, 2016

Expires: August 11, 2017

Activities

Heme Malignancies Chicago 2016
Expert Perspective on the Top Hematologic Malignancy Studies From the 2016 Clinical Oncology Meeting
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: May 31, 2016

Expires: May 30, 2017

Meta-analysis of Len Maintenance in MM
Lenalidomide Maintenance after ASCT Improved OS in Newly Diagnosed MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2016

Expires: June 05, 2017

KPd in R/R MM
Carfilzomib, Pomalidomide, Dexamethasone Feasible in Patients With Relapsed/Refractory MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2016

Expires: June 05, 2017

CTL019 Dosing in R/R ALL
Fractionated Dosing Optimizes CAR T-Cell Therapy in Adult Relapsed/Refractory ALL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2016

Expires: June 05, 2017

19-28z CAR T Cells in R/R B-Cell ALL
19-28z CAR T-Cell Efficacy and Toxicity in Adults With R/R B-Cell ALL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2016

Expires: June 05, 2017

VEN+LDAC in Untreated AML
Venetoclax + Low-Dose Cytarabine in Elderly Patients With Untreated AML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2016

Expires: June 05, 2017

Venetoclax in CLL
Venetoclax Active in Relapsed/Refractory CLL After Treatment With Ibrutinib or Idelalisib
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2016

Expires: June 05, 2017

Ruxolitinib in MF
COMFORT-1: Final 5-Yr Analysis of Ruxolitinib in Int- or High-Risk Myelofibrosis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2016

Expires: June 06, 2017

Mogamulizumab in R/R ATL
0761-009: Mogamulizumab in R/R Adult T-Cell Leukemia-Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2016

Expires: June 06, 2017

ASCT Prolongs PFS in NDMM
Phase III EMN02/HO95 MM Trial: Upfront ASCT Prolongs PFS vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2016

Expires: June 06, 2017

CPX-351 in High-Risk AML
First-line CPX-351 Superior to 7 + 3 Induction in Older Patients With High-Risk AML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2016

Expires: June 07, 2017

Acalabrutinib in CLL
Phase II Study of Acalabrutinib Monotherapy Demonstrates Activity, Safety in Previously Untreated CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2016

Expires: June 07, 2017

Pembrolizumab in R/R MM
KEYNOTE-023: Pembrolizumab + Lenalidomide + Dexamethasone Shows Promising Activity and Safety in R/R MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2016

Expires: June 07, 2017

CASTOR: DVd vs Vd in MM
CASTOR: Daratumumab Added to Bortezomib/Dexamethasone Improves PFS, Response in RR Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2016

Expires: June 07, 2017

Venetoclax + Vd in R/R MM
Phase Ib Venetoclax With Bortezomib and Dexamethasone Safe, Active in R/R MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2016

Expires: June 08, 2017

Carfilzomib in R/R MM
Economic Evaluation: Addition of Carfilzomib to Lenalidomide/Dexamethasone Cost Effective for R/R MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2016

Expires: June 09, 2017

TKI Comparison in Ph+ ALL
First-line HCVAD + Ponatinib Appears Superior to HCVAD + Dasatinib in Ph+ ALL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 13, 2016

Expires: June 12, 2017

KRD in Early Relapsed MM
Carfilzomib/Lenalidomide/Low-Dose Dexamethasone in MM With Early Progression: ASPIRE Subgroup Analysis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 14, 2016

Expires: June 13, 2017

LEN in CNS Lymphoma
Lenalidomide Shows Promising Activity in Recurrent CNS Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 14, 2016

Expires: June 13, 2017

Downloadable Slideset
Hematologic Malignancies: A Review of Key Clinical Studies
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: August 30, 2016

Expires: August 29, 2017

Activities

Lung Cancer ASCO 2016
Lung Cancer: Looking Ahead to the 2016 Clinical Oncology Meeting
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: May 31, 2016

Expires: May 30, 2017

LURET: Phase II Study of Vandetanib
Phase II LURET Study: Vandetanib Monotherapy Active in RET-Rearranged Advanced NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2016

Expires: June 05, 2017

NSCLC Anti–PD-1 Past Progression
FDA Analysis: Metastatic NSCLC Treated With Anti–PD-1 Therapy Past RECIST Progression
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2016

Expires: June 05, 2017

BID vs QD CRT in SCLC
Phase III CONVERT: Twice-Daily vs Once-Daily Concurrent CRT in Limited-Stage SCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2016

Expires: June 06, 2017

CRZ in <i>MET</i>-Rearranged NSCLC
PROFILE 1001: Crizotinib in Advanced Non-Small-Cell Lung Cancer With MET Exon 14 Alterations
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2016

Expires: June 06, 2017

Lorlatinib in ALK/ROS1+ NSCLC
Phase I/II Study of Lorlatinib in Advanced ALK+ or ROS1+ NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2016

Expires: June 06, 2017

Rovalpituzumab Tesirine in SCLC
Rovalpituzumab Tesirine Safe, Active in Previously Treated SCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2016

Expires: June 06, 2017

Chemotherapy in Early-Stage NSCLC
E1505: Similar Survival Across 4 Different Chemotherapy Regimens in Early-Stage, Resected NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2016

Expires: June 07, 2017

LCT in Oligometastatic NSCLC
Local Consolidative Therapy in Oligometastatic NSCLC With No Progression on First-line Systemic Treatment
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2016

Expires: June 08, 2017

Osimertinib in NSCLC With LM
BLOOM: Osimertinib Shows Promising Activity in Patients With EGFRm+ Advanced NSCLC and Leptomeningeal Metastases
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2016

Expires: June 09, 2017

Alectinib in ALK+ NSCLC
Phase III J-ALEX: Alectinib vs Crizotinib in ALK Inhibitor–Naïve, ALK-Positive NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2016

Expires: June 09, 2017

Brigatinib in ALK+ NSCLC
Phase II ALTA: Brigatinib Has Promising Activity in Crizotinib-Refractory ALK+ NSCLC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 13, 2016

Expires: June 12, 2017

Downloadable Slideset
Lung Cancer: A Review of Key Clinical Studies
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: August 17, 2016

Expires: August 16, 2017

Activities

Practice-Changing Data in Breast Cancer
Breast Cancer: A Look Ahead to Practice-Changing Data at the 2016 Clinical Oncology Meeting
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: May 31, 2016

Expires: May 30, 2017

Breast Cancer Resection
Phase III MF07-01 Trial: Impact of Initial Local Resection on Stage IV Breast Cancer Survival
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2016

Expires: June 05, 2017

T-DM1 + P vs TCH + P in HER2+ EBC
KRISTINE: Neoadjuvant T-DM1 + Pertuzumab vs Chemotherapy With Trastuzumab + Pertuzumab in HER2+ EBC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2016

Expires: June 05, 2017

Abemaciclib Active in HR+ MBC
Phase II MONARCH 1: CDK4/6 Inhibitor Abemaciclib in HR+/HER2- MBC After Chemotherapy
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2016

Expires: June 05, 2017

Atezolizumab in mTNBC
Atezolizumab + Nab-Paclitaxel Well Tolerated and Active in Metastatic TNBC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2016

Expires: June 06, 2017

MA.17R: Benefit of Extended Letrozole
MA.17R: Reduced Risk of Recurrence With Extending Adjuvant Letrozole Beyond 5 Yrs in Postmenopausal Women With Early-Stage Breast Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2016

Expires: June 06, 2017

TC vs TaxAC in HER2- EBC
ABC Trials Joint Analysis: TC vs TaxAC in High-Risk, HER2-Negative Early Breast Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2016

Expires: June 06, 2017

Second-line Pertuzumab in HER2+ MBC
PHEREXA: No PFS Benefit of Adding Pertuzumab to Trastuzumab + Capecitabine in HER2+ MBC Progressing on or After Trastuzumab-Based Therapy
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2016

Expires: June 08, 2017

Palbociclib in ER+ Breast Cancer
PALOMA-2: Addition of Palbociclib to Frontline Letrozole Significantly Improves PFS in Postmenopausal ER+/HER2- Advanced Breast Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 14, 2016

Expires: June 13, 2017

Downloadable Slideset
Breast Cancer: A Review of Key Clinical Studies
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: August 16, 2016

Expires: August 15, 2017

Activities

Atezolizumab in First-line mUC
IMvigor 210 (Cohort 1): First-line Atezolizumab in Cisplatin-Ineligible Metastatic Urothelial Carcinoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2016

Expires: June 05, 2017

MASTERKEY-265
MASTERKEY-265: T-VEC + Pembrolizumab Safe, Active in Unresectable Stage IIIB/IV Melanoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2016

Expires: June 05, 2017

CTL019 Dosing in R/R ALL
Fractionated Dosing Optimizes CAR T-Cell Therapy in Adult Relapsed/Refractory ALL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2016

Expires: June 05, 2017

Atezolizumab in Pretreated mUC
IMvigor 210 (Cohort 2): Atezolizumab in Pretreated Metastatic Urothelial Carcinoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2016

Expires: June 05, 2017

NSCLC Anti–PD-1 Past Progression
FDA Analysis: Metastatic NSCLC Treated With Anti–PD-1 Therapy Past RECIST Progression
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2016

Expires: June 05, 2017

Atezolizumab in mTNBC
Atezolizumab + Nab-Paclitaxel Well Tolerated and Active in Metastatic TNBC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 07, 2016

Expires: June 06, 2017

Pembrolizumab in R/R MM
KEYNOTE-023: Pembrolizumab + Lenalidomide + Dexamethasone Shows Promising Activity and Safety in R/R MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2016

Expires: June 07, 2017

Pembrolizumab in MMRD CRC
Pembrolizumab Shows Promising Activity in Mismatch Repair–Deficient CRC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2016

Expires: June 08, 2017

Nivo Beyond Progression in RCC
Potential Benefit of Nivolumab Treatment Beyond Progression in Advanced RCC: Subgroup Analysis of CheckMate 025
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2016

Expires: June 08, 2017

Pembrolizumab in Advanced CC
KEYNOTE-028: Pembrolizumab in PD-L1+ Advanced Cervical Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2016

Expires: June 08, 2017

MEK/PD-L1 Combo in mCRC
Cobimetinib + Atezolizumab Well Tolerated and Shows Promising Activity in KRAS-Mutant mCRC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2016

Expires: June 09, 2017

Pembrolizumab in Melanoma
KEYNOTE-006: Final OS Analysis of Pembrolizumab vs Ipilimumab for Advanced Melanoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 13, 2016

Expires: June 12, 2017

Pembro + Ipili in Advanced Melanoma
KEYNOTE-029 Expansion Cohort: Pembrolizumab + Ipilimumab Safe, Active in Advanced Melanoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 14, 2016

Expires: June 13, 2017

Immunoscore in CRC
Immunoscore Prognostic in Colon Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 14, 2016

Expires: June 13, 2017

Atezolizumab Predictors of Response
IMvigor210: Predictors of Response to Atezolizumab in mUC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 14, 2016

Expires: June 13, 2017

Downloadable Slideset
Immunotherapy: A Review of Key Clinical Studies
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 19, 2016

Expires: September 18, 2017

Activities

GOG0213: Repeat Bevacizumab in EOC
GOG0213: Bevacizumab Retreatment of Recurrent Platinum-Sensitive Ovarian Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2016

Expires: June 05, 2017

Olaparib in PS-SOC
Long-term Follow-up of Olaparib Maintenance Monotherapy in Platinum-Sensitive Serous Ovarian Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2016

Expires: June 07, 2017

IP vs IV Chemo in EOC
OV21/PETROC: IP vs IV Chemo After Neoadjuvant Chemo and Optimal Cytoreduction in Epithelial Ovarian Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2016

Expires: June 08, 2017

Pembrolizumab in Advanced CC
KEYNOTE-028: Pembrolizumab in PD-L1+ Advanced Cervical Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2016

Expires: June 08, 2017

Activities

Sidedness is Important in mCRC
Tumor Location Prognostic and Predictive in KRAS wt mCRC: Retrospective Analysis of CALGB/SWOG 80405
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2016

Expires: June 07, 2017

Pembrolizumab in MMRD CRC
Pembrolizumab Shows Promising Activity in Mismatch Repair–Deficient CRC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2016

Expires: June 08, 2017

MEK/PD-L1 Combo in mCRC
Cobimetinib + Atezolizumab Well Tolerated and Shows Promising Activity in KRAS-Mutant mCRC
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2016

Expires: June 09, 2017

TAS-102 in mCRC
Trifluridine/Tipiracil (TAS-102) Improves Survival in Patients With Metastatic CRC and Mild Renal/Hepatic Impairment: Subgroup Analysis of RECOURSE
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 13, 2016

Expires: June 12, 2017

GEMCAP vs CAP in Pancreatic Cancer
ESPAC-4: Adjuvant Gemcitabine/Capecitabine Improves 5-Yr Survival vs Gemcitabine Alone in Resected Pancreatic Ductal Carcinoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 14, 2016

Expires: June 13, 2017

Immunoscore in CRC
Immunoscore Prognostic in Colon Cancer
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 14, 2016

Expires: June 13, 2017

Activities

MASTERKEY-265
MASTERKEY-265: T-VEC + Pembrolizumab Safe, Active in Unresectable Stage IIIB/IV Melanoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2016

Expires: June 05, 2017

NEMO: Binimetinib in <i>NRAS</i>-mutant Melanoma
NEMO: Binimetinib Shows Promising Activity in NRAS-Mutant Cutaneous Melanoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2016

Expires: June 09, 2017

Pembrolizumab in Melanoma
KEYNOTE-006: Final OS Analysis of Pembrolizumab vs Ipilimumab for Advanced Melanoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 13, 2016

Expires: June 12, 2017

Pembro + Ipili in Advanced Melanoma
KEYNOTE-029 Expansion Cohort: Pembrolizumab + Ipilimumab Safe, Active in Advanced Melanoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 14, 2016

Expires: June 13, 2017

Faculty

cover img faculity

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

cover img faculity

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

cover img faculity

Brian I. Rini, MD

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio

cover img faculity

Heather Wakelee, MD

Associate Professor of Medicine, Oncology
Department of Medicine/Oncology
Stanford University/Stanford Cancer Institute
Stanford, California

Provided by

ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.